ARCHIVES

In Sign-Off Of Two Orphan Drugs, ODAC Leaves Efficacy Interpretation To Docs

This article is from The Cancer Letter archive.

Vol. 24 No. 45 | November 27, 1998

Download PDF Visit The Full Archive

Related Articles

Cedars-Sinai Develops Criteria For FDG-PET In Breast Cancer

August 25, 2006

President’s Cancer Panel annual report finds barriers in translational research stall progress.

July 8, 2005

NCI Advisors Approve Research Network On Screening

August 6, 2010

In Brief: $100 Million Being Spent On Interferon In U.S., Rauscher Says; DeVita; Criticism Deserved

April 4, 1980

Mass. Law Requires Reimbursement For Off-Label Cancer Drugs

January 22, 1993

Opdivo Study Shows 41 Percent One-Year Survival In Patients With at Least Two Past Therapies

November 28, 2014